Carboplatin Alone vs Carboplatin plus Epidoxorubicin as Second-Line Therapy for Cisplatin- or Carboplatin-Sensitive Ovarian Cancer

作者: Giorgio Bolis , Giovanna Scarfone , Giorgio Giardina , Antonella Villa , Giorgia Mangili

DOI: 10.1006/GYNO.2001.6151

关键词: CisplatinRandomizationUrologyCarboplatinChemotherapyOvarian cancerSurgeryCarcinomaDiscontinuationLeukopeniaMedicineObstetrics and gynaecologyOncology

摘要: Abstract Objective. The aim of the study was to analyze benefit/toxicity profile a second-line treatment with carboplatin alone or plus another non-cross-resistant drug (epidoxorubicin) in ovarian cancer patients sensitive cisplatin-based chemotherapy at first-line treatment. Methods. We conducted randomized clinical trial. Women epithelial FIGO Stage II–IV who had complete partial response cisplatin carboplatin-based regiments and subsequently progressed relapsed more than 6 months after discontinuation were eligible for study. A total 190 subjects entered They randomly allocated either 300 mg/m 2 every 28 days five cycles (95 patients) 120 epidoxorubicin patients). Results. reported, respectively, 32 (36%) women (31.8%) those epidoxorubicin. corresponding figures 18 (20.2%) 26 (29.9%). Comparing frequency response, no change, progression, differences between two groups not significant (χ 3 5.10, P = 0.16). median duration 16 20 group ( significant). 3-year percentage survival 29% 42% group; this difference statistically significant. leukopenia, anemia, thrombocytopenia grade 3–4 higher group. Alopecia G3 present 88% treated carboplatin. Conclusions. general results do show any marked among single-agent (carboplatin) multiagent (carboplatin epidoxorubicin) schedules. Toxicity, particularly hematological, relevant schedule.

参考文章(18)
David R. Cox, Regression Models and Life-Tables Springer Series in Statistics. ,vol. 34, pp. 527- 541 ,(1992) , 10.1007/978-1-4612-4380-9_37
J.P. Guastalla, E. Pujade-Lauraine, B. Weber, H. Curé, H. Orfeuvre, M. Mousseau, P. Vincent, V. Diéras, N. Tubiana-Mathieu, J.P. Jacquin, L. Mignot, B. Leduc, P. Viens, D. Pariso, Efficacy and safety of the paclitaxel and carboplatin combination in patients with previously treated advanced ovarian carcinoma A multicenter GINECO (Groupe d'Investigateurs Nationaux pour l'Etude des Cancers Ovariens) phase II study Annals of Oncology. ,vol. 9, pp. 37- 43 ,(1998) , 10.1023/A:1008211909585
C. Mangioni, G. Bolis, S. Pecorelli, K. Bragman, A. Epis, G. Favalli, A. Gambino, F. Landoni, M. Presti, W. Torri, L. Vassena, F. Zanaboni, S. Marsoni, Randomized Trial in Advanced Ovarian Cancer Comparing Cisplatin and Carboplatin Journal of the National Cancer Institute. ,vol. 81, pp. 1464- 1471 ,(1989) , 10.1093/JNCI/81.19.1464
Stephen A. Cannistra, Cancer of the Ovary New England Journal of Medicine. ,vol. 329, pp. 1550- 1559 ,(1993) , 10.1056/NEJM199311183292108
R Peto, M C Pike, P Armitage, N E Breslow, D R Cox, S V Howard, N Mantel, K McPherson, J Peto, P G Smith, Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. analysis and examples. British Journal of Cancer. ,vol. 35, pp. 1- 39 ,(1977) , 10.1038/BJC.1977.1
Giorgio Bolis, Fabio Parazzini, Giovanna Scarfone, Antonella Villa, Mariangela Amoroso, Emanuela Rabaiotti, Anna Polatti, Simona Reina, Elena Pirletti, Paclitaxel vs Epidoxorubicin plus Paclitaxel as Second-Line Therapy for Platinum-Refractory and -Resistant Ovarian Cancer Gynecologic Oncology. ,vol. 72, pp. 60- 64 ,(1999) , 10.1006/GYNO.1998.5237
M.E. Gore, I. Fryatt, E. Wiltshaw, T. Dawson, Treatment of relapsed carcinoma of the ovary with cisplatin or carboplatin following initial treatment with these compounds Gynecologic Oncology. ,vol. 36, pp. 207- 211 ,(1990) , 10.1016/0090-8258(90)90174-J
J.E. Kurtz, G. Deplanque, B. Duclos, F. Eichler, C. Giron, J.M. Limacher, R. Herbrecht, F. Maloisel, F. Oberling, J.P. Bergerat, P. Dufour, Paclitaxel–Anthracycline Combination Chemotherapy in Relapsing Advanced Ovarian Cancer after Platinum-Based Chemotherapy: A Pilot Study Gynecologic Oncology. ,vol. 70, pp. 414- 417 ,(1998) , 10.1006/GYNO.1998.5099
P. Kenemans, J. B. Vermorken, G. Bolis, M. A. Lentz, A. Kobierska, R. E N Van Rijswijk, F. Zanaboni, H. M. Pinedo, C. W. Burger, B. Chevallier, M. E L Van der Burg, High-dose intensity regimens with epirubicin in ovarian cancer. Seminars in Oncology. ,vol. 21, pp. 17- 22 ,(1994)
M Markman, R Rothman, T Hakes, B Reichman, W Hoskins, S Rubin, W Jones, L Almadrones, J L Lewis, Second-line platinum therapy in patients with ovarian cancer previously treated with cisplatin. Journal of Clinical Oncology. ,vol. 9, pp. 389- 393 ,(1991) , 10.1200/JCO.1991.9.3.389